NCT02787083View on ClinicalTrials.gov

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis

PHASE3TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

July 5, 2019

Study Completion Date

July 5, 2019

Conditions
Cystitis, Interstitial
Interventions
DRUG

Mirabegron

DRUG

Placebo

Trial Locations (1)

19107

Philadelphia Urosurgical Associates, Philadelphia

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Global Development, Inc.

INDUSTRY

lead

Philadelphia Urosurgical Associates

OTHER

NCT02787083 - A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis | Biotech Hunter | Biotech Hunter